Insights of Breast Cancer and Barriers to its Therapy

  • Nidhi Garg Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India
  • Suman Baishnab Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India
  • Rosy Das Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India
  • Kiranjeet Kaur Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India
  • Saurabh Gupta Department of Pharmacy Practice & Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh Patiala National Highway (NH64), Punjab–140401, India
  • Sandeep Arora Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India
Keywords: Breast Cancer, Carcinoma, Tumour, Barriers

Abstract

Breast cancer is the most common cancer across the globe occurring commonly in women population, and it is one of the main causes of mortality in women. In 2018, 1,62,468 new cases and 87,090 death cases of breast cancer were registered in India. In these recent years, lots of studies were conducted in breast cancer related to treatment and management, but in spite of getting so much advancement in the treatment of breast cancer still, the mortality rate of women is increasing day by day. Numerous factors are acting as barriers or challenges in breast cancer preventive therapy. It includes lack of knowledge regarding the treatment of cancer and patient getting insecure about treatment, fear of having side effects, cost of treatment and the efficacy of the drugs being prescribed. The study intended to determine the perceived insights and barriers to treatment of breast cancer.

Downloads

Download data is not yet available.

References

Adhikary, A., Chakraborty, D., Indu, R., Bhattacharya, S., Ray, M., Mukherjee, R. (2018). Drug prescription pattern of breast cancer patients in a tertiary care hospital in West Bengal: A Cross-Sectional and Questionnaire-Based Study. Asian journal of pharmaceutical and clinical research, 11(3), 398-401. https://doi.org/10.22159/ajpcr.2018.v11i3.23180

Adhikary, et al. (2018). Drug prescription pattern of breast cancer patients in a tertiary care hospital in West Bengal: A Cross-Sectional and Questionnaire-Based Study. Asian journal of pharmaceutical and clinical research, 11(3), 398-401.

Alco, G., Igdem, S. & Dincer, M. (2014). Vitamin D levels in patients with breast cancer: importance of dressing style. Asian Pac J Cancer Prev, 15, 1357-62. https://doi.org/10.7314/APJCP.2014.15.3.1357

Anuradha, D. & Lakshmi A. (2017). Mucinous carcinoma of breast with neuroendocrine differentiation: a rare case report with review of literature. Int J Res Med Sci, 2, 1751-4. https://doi.org/10.5455/2320-6012.ijrms201411102

Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res, 6, 149-52. https://doi.org/10.1186/bcr767

Bednarek, A., Sahin, A., Brenner, A., Johnston, D. & Aldaz, C. (1997). Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res, 3(1), 11-6.

Bray, F., Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D. (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 136, E359-E386. https://doi.org/10.1002/ijc.29210

Cariati, M., Bennett-Britton, T. M., Pinder, S. E., Purushotham, A. D. (2005). Inflammatory breast cancer. Surg Oncol, 14, 133-43.

Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., et al. (2006). Catechol oestrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta, 1766, 63-8. https://doi.org/10.1016/j.bbcan.2006.03.001

Chopra, D., Rehan, H. S., Sharma, V., Mishra, R. (2016). Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatr Oncol, 37, 42-6. https://doi.org/10.4103/0971-5851.177015

Clauser, P., Marino, M. A., Baltzer, P. A., Bazzocchi, M., Zuiani, C. (2016). Management of atypical lobular hyperplasia, a typical ductal hyperplasia, and lobular carcinoma in situ. Exp Rev Anticancer ther, 16, 335-6.

Corbelli, J., Borrero, S., Bonnema, R., et al. (2014). Use of the Gail model and breast cancer preventive therapy among three primary care specialties. J Women’s Health, 23, 746-52. https://doi.org/10.1089/jwh.2014.4742

Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicol Pathol, 35, 495-516. https://doi.org/10.1080/01926230701320337

Errichetti, E., Avellini, C., Pegolo, E., De Francesco, V. (2017). Dermoscopy as a supportive instrument in the early recognition of erosive adenomatosis of the nipple and mammary paget’s disease. Ann Dermatol, 29, 365-7. https://doi.org/10.5021/ad.2017.29.3.365

Evan, G. and Vousden, K. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8. https://doi.org/10.1038/35077213

Feuer, E. J., Wun, L. M., Boring, C. C., Flanders, W. D., Timmel, M. J., Tong, T. (1993). The Lifetime Risk of Developing Breast Cancer. JNCI Journal of the National Cancer Institute, 85(11), 892-897. https://doi.org/10.1093/jnci/85.11.892

Franca, A., Ferreira, M., Franca, J., Franca, E., Honorio- Franca, A. (2012). Breastfeeding and its relationship with reduction of breast cancer: a review. Asian Pac J Cancer Prev, 13, 5327-32. https://doi.org/10.7314/APJCP.2012.13.11.5327

Garrone, O., Miraglio, E. Vandone, A.M., Vanella, P., Lingua, D., Merlano, M. C. (2017). Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Future Oncol, 13(30), 2759-2769. https://doi.org/10.2217/fon-2017-0283

Gerratana, L., Bonotto, M., Bozza, C., Ongaro, E., Fanotto, V., Pelizzari, G., Puglisi, F. (2017). Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. https://doi.org/10.1080/14712598.2017.1282944

Gupta, G. & Massagué, J. (2006). Cancer metastasis: building a framework. Cell, 127, 679-95. https://doi.org/10.1016/j.cell.2006.11.001

Gusterson, B., Warburton, M. J., Mitchell, D., Ellison, M., Neville, A.M. & Rudland, P.S. (1982). Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res, 42, 4763-70.

Hanahan, D. and Weinberg, R. (2000). The hallmarks of cancer. Cell, 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9

Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., et al. (2016). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. J Clin Oncol, 34, 1134-50. https://doi.org/10.1200/JCO.2015.65.2289

Harris, R. E., Chlebowski, R. T., Jackson, R. D., et al. (2003). Prospective Results from the Women’s Health Initiative Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs. Cancer Res, 63, 6096-6101.

Heim, E., Valach, L. & Schaffner, L. (1997). Coping and psychosocial adaptation: longitudinal effects over time and stages in breast cancer. Psychosom Med, 59, 408-18. https://doi.org/10.1097/00006842-199707000-00011

Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.Y., Fehrenbacher, L., Gomez, S. L., Miles, S., and Neugut, A.I. (2010).Early discontinuation and Nonadherence to Adjuvant Hormonal Therapy. J Clin Oncol, 28(27), 4120-4128. https://doi.org/10.1200/JCO.2009.25.9655

Holmberg, C., Waters, E. A,, Whitehouse, K. et al. (2015). My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision making about participation in the study of tamoxifen and raloxifene (STAR). Med Decis Mak, 35, 1010-22. https://doi.org/10.1177/0272989X15594382

Hum, S., Wu, M., Pruthi, S., Heisey, R. (2016). Physician and Patient Barriers to Breast Cancer Preventive Therapy. Curr Breast Cancer Rep., 8, 158-164. https://doi.org/10.1007/s12609-016-0216-5

India today: https://www.indiatoday.in/pti-feed/story/over-17-lakh-new-cancer-cases-in-india-by-2020-icmr-610839-2016-05-18.

Inoue, M., Nakagomi, H., Nakada, H., Furuya, K., Ikegame, K. & Watanabe, H. (2017). Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer, 20, 1-6. https://doi.org/10.1007/s12282-017-0753-4

Jacobs, T., Byrne, C., Colditz, G., Connolly, J., Schnitt, S. (1999). Radial scars in benign breast-biopsy specimens and the risk of breast cancer. New Engl J Med., 340, 430-6. https://doi.org/10.1056/NEJM199902113400604

Jacquillat, C., Weil, M., Baillet, F., Borel, C., Auclerc, G. & Maublanc, M. (1990). Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer, 66, 119-29.

Jain, R. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819

Jarde, T., Perrier, S., Vasson, M., Caldefie-Chezet, F. (2011). Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer, 47, 33-43. https://doi.org/10.1016/j.ejca.2010.09.005

Joglekar-Javadekar, M., Van, L. S., Bourne, M., Moalwi, M., Finetti, P., Vermeulen, P. B., et al. (2017). Characterization and targeting of platelet-derived growth factor receptor alpha (PDGFRA) in inflammatory breast cancer (IBC). Neoplasia. 2017; 19, 564-73. https://doi.org/10.1016/j.neo.2017.03.002

Kanwal, R., Gupta, S. (2012). Epigenetic modifications in cancer. Clin. Genet., 81(4), 303-11. https://doi.org/10.1111/j.1399-0004.2011.01809.x

Karen, E. L., Paul, D. A., Steffie, J. W., David, U. H., Sidney, M. W., David, H. B. (2002). Timings of New Black Box warnings and withdrawals for Prescription medications. JAMA, 287, 2215-2220. https://doi.org/10.1001/jama.287.17.2215

Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., Paszat, L. F. (2010). Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population-based cohort study. BMJ, 340, c693. https://doi.org/10.1136/bmj.c693

Kelsey, J. & Bernstein, L. (1996). Epidemiology and prevention of breast cancer. Ann Rev Public Health, 17, 47-67.

Kristeen Cherney. (2018). 12 effects of breast cancer on the body. MPH.

Kulkarni, V., Bora, S. S., Sirisha, S., Saji, M., Sundaran, S. (2013). A study on drug-drug interactions through prescription analysis in a South Indian teaching hospital. Therapeutic Advances in Drug Safety, 4(4), 141-146. https://doi.org/10.1177/2042098613490009

Lai, J. N., Wu, C. T., Wang, J. D. (2012). Prescription pattern of Chinese herbal products for breast cancer in Taiwan: a population-based study. Evid Based Complement Alternat Med, 891893. https://doi.org/10.1155/2012/891893

Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81. https://doi.org/10.1200/JCO.2007.14.4147

Loibl, S., Denkert, C., Von Minckwitz, G. (2015). Neoadjuvant treatment of breast cancer - Clinical and research perspective. The Breast, 24(S2), S73-S77. http://dx.doi.org/10.1016/j.breast.2015.07.018

Longo, D. L. (2012). Cancer cell biology and angiogenesis. Harrison’s Principles of Internal Medicine, 693.

López-Tarruella, S., Jerez, Y., Márquez-Rodas, I., Echavarria, I., Martin, M. (2017). Ribociclib for treatment of advanced HER2-negative breast cancer. Future oncol. https://doi.org/10.2217/fon-2017-0183

Malvia, S., Bagadi, S. A., Dubey, U. S. & Saxena, S. (2017). Epidemiology of breast cancer in Indian women. Asia-Pacific Journal of Clinical Oncology, 10, 1-7. https://doi.org/10.1111/ajco.12661

Manichavasagam, M., et al. (2017). Prescribing Pattern of Anticancer Drugs in a Medical Oncology Department of a Tertiary Care Teaching Hospital. Ann Med Health Sci Res, 7, 1-3.

Martín- Martín, M. (2015). A review on nab-Paclitaxel dose and schedule in breast cancer. Cancer Research, 17(81). https://doi.org/10.1186/s13058-015-0587-y

Mateo, A., Pezzi, T., Sundermeyer, M., Kelley, C., Klimberg, V., Pezzi, C. (2017). Chemotherapy significantly improves survival for patients with T1c-T2N0M0 medullary Breast cancer. Ann Surg Oncol, 24, 1050-6.

McPherson, K., Steel, C., Dixon, J. (2003). Breast cancerepidemiology, risk factors, and genetics. Brit Med J, 321, 624-8.

Merrill, A., White, A., Howard-McNatt, M. (2017). Paget’s disease of the breast: an institutional review and surgical management. Am Surg, 83, 96-8.

Moran, M., Schnitt, S., Giuliano, A., Harris, J., Khan, S. & Horton, J. (2014). Society of surgical oncology-American society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Rad Oncol Biol Phys, 88, 553-64.

https://doi.org/10.1016/j.ijrobp.2013.11.012

Murthy, N. S., Rajaram, D., Gautham, M. S., Shivaraj, N. S., Nandakumar, B. S., Pruthvish, S. (2011). Risk of cancer development in India. Asian Pac J Cancer Prev, 12, 387-91.

Nakatsukasa, K. et al. (2016). Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. The Japanese Breast Cancer Society. Springer. https://doi.org/10.1007/s12282-016-0666-7

Nakhlis, F. & Morrow, M. (2003). Ductal carcinoma in situ. Surg Clin, 83, 821-39. https://doi.org/10.1016/S0039-6109(03)00072-0

National Cancer Institute. (2012). Fact sheet: targeted cancer therapies, 2012. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1.

Neuman, H. B., Morrogh, M., Gonen, M., Van Zee, K. J., Morrow, M., & King, T. A. (2010). Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter. Cancer, 116(5), 1226-1233. https://doi.org/10.1002/cncr.24873

Nkondjock, A. & Ghadirian, P. (2004). Epidemiology of breast cancer among BRCA mutation carriers: an overview. Cancer Lett, 205, 1-8.

Nozad, S., Sheehan, C., Gay, L., Elvin, J., Vergilio, J., Suh, J., et al. (2017). Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat, 162, 597-602. https://doi.org/10.1007/s10549-017-4156-1

Page, K., Guttery, D., Fernandez-Garcia, D., Hills, A., Hastings, R., Luo, J., et al. (2017). Next-generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. Clin Chem, 63, 532-41. https://doi.org/10.1373/clinchem.2016.261834

Palanisamy, R. P. (2017). Palbociclib: A new hope in the treatment of breast cancer. J Can Res Ther, 2, 1220-3. https://doi.org/10.4103/0973-1482.168988

Park, K. (2015). Park’s Textbook of Preventive and Social Medicine. Jabalpur: Banarasidas Bhanot, 389.

Patel, N. et al. (2016). A study of medication errors in a tertiary care hospital. Indian Society for Clinical Research, 7(4), 168-173.

Peng, J., Sengupta, S., & Jordan, V. C. (2009). Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anti-cancer agents in medicinal chemistry, 9(5), 481-499.

Pentareddy, M. R., Suresh, A. V. S., Shailendra, D., Subbaratnam, Y., Prasuna, G., Naresh, D. T. V., Rajshekar, K. (2015). Prescription Pattern of Anticancer Drugs in a Tertiary Care Hospital. Journal of Evidence-based Medicine and Healthcare, 2(20), 3001- 9. https://doi.org/10.18410/jebmh/2015/435

Posner, M. C. & Wolmark, N. (1992). Non-invasive breast carcinoma. Breast Cancer Res Treat, 21(3), 155-64. https://doi.org/10.1007/BF01974998

Prabhakaran, S., Rizk, V., Ma, Z., Cheng, C., Berglund, A., Coppola, D., et al. (2017). Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. Breast Cancer Res, 19, 71-4. https://doi.org/10.1186/s13058-017-0864-z

Priya, V. & Prasaad, P. (2017). Tubulo-lobular carcinoma: a rare mixed invasive carcinoma of breast. Int J Res Med Sci, 5, 2818-20.

Reeder, J., Vogel, V. (2008). Breast cancer prevention. Cancer Treat Res, 141, 149-164. https://doi.org/10.1007/978-0-387-73161-2_10

Reiter, F. J., Rosales-Corral, S. A., Tan, D. X., Acuna-Castroviejo, D., Qin, L., Yang, S. F., Melatonin, K. X. (2017). A Full-Service Anti-Cancer Agent: Inhibition

of Initiation, Progression and Metastasis. Int. J. Mol. Sci, 18, 843. https://doi.org/10.3390/ijms18040843

Scharl, A., Salterberg, A., Untch, M., Liedtke, C., Stickeler, E., Papathemelis, T. (2016). Treatment modification in young breast cancer patient. Oncol Res Treat, 39, 122-128. https://doi.org/10.1159/000444355

Segal, R., Evans, W., Johnson, D., Smith, J., Colletta, S. & Gayton, J. (2001). Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol, 19, 657-65. https://doi.org/10.1200/JCO.2001.19.3.657

Sera, T., Kashiwagi, S., Takashima, T., Asano, Y., Goto, W., Iimori, N., et al. (2017). Multiple metastatic malignant phyllodes tumor of the breast with tonsillar metastasis: a case report. BMC Res Notes, 10, 55-60. https://doi.org/10.1186/s13104-017-2375-5

Seyfried, T. N. & Huysentruyt, L. C. (2013). On the origin of cancer metastasis. Crit Rev Oncog, 18, 43-73. https://doi.org/10.1615/CritRevOncog.v18.i1-2.40

Shalini, S., Ravichandran, V., Mohanty, B. K., Dhanaraj, S. K., Sraswathi, R. (2010). Drug utilization studies - An overview. Int J Pharm Sci Nanotech, 3, 803-810.

Sjoqvist, F., Birkettm D. (2003). Drug utilization. WHO Booklet. Sweden, Australia: WHO.

Somiari, R., Sullivan, A., Russell, S., Somiari, S., Hu, H., Jordan, R., George, A., Katenhusen, R., Buchowiecka, A., Arciero, C., Brzeski, H. (2003). High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics, 3(10), 1863-73. https://doi.org/10.1002/pmic.200300560

Stevanovic, A., Lee, P. & Wilcken, N. (2006). Metastatic breast cancer. Aust Fam Phys, 35, 309-11.

Stingl, J., Raouf, A., Eirew, P. & Eaves, C. J. (2006). Deciphering the mammary epithelial cell hierarchy. Cell Cycle, 5, 1519-22.

Stingl, J., Raouf, A., Emerman, J. T. & Eaves, C. J. (2005). Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol Neoplasia, 10, 49-59. https://doi.org/10.1007/s10911-005-2540-7

Tan, D., Marchió, C., Jones, R., Savage, K., Smith, I., Dowsett, M. (2008). Triple-negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat., 111, 27-44. https://doi.org/10.1007/s10549-007-9756-8

West, A., Wullkopf, L., Christensen, A., Leijnse, N., Tarp, J. M., Mathiesen, J., et al. (2017). Division induced dynamics in non-Invasive and invasive breast cancer. Biophys J, 112, 123-5. https://doi.org/10.1016/j.bpj.2016.11.687

Zhao, M., Ding, X. F., Shen, J. Y., Zhang, X. P., Ding, X. W., Bin, X. U. (2017). Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice Journal of Zhejiang University. SCIENCE B (Biomedicine & Biotechnology). https://doi.org/10.1631/jzus.B1600303

Ziperstein, M. J., Guzman, A. & Kaufman, L. J. (2016). Evaluating breast cancer cell morphology as a predictor of invasive capacity. Biophys J, 110, 621-5. https://doi.org/10.1016/j.bpj.2015.11.3333

Published
2019-11-05
How to Cite
Nidhi Garg, Suman Baishnab, Rosy Das, Kiranjeet Kaur, Saurabh Gupta, & Sandeep Arora. (2019). Insights of Breast Cancer and Barriers to its Therapy. Journal of Pharmaceutical Technology, Research and Management, 7(2), 73-86. https://doi.org/10.15415/jptrm.2019.72010
Section
Articles